New approach to detect and treat metastatic cancers using a specific protein target.
A novel molecularly targeted theranostic approach via the alphavbeta6 integrin for the detection and treatment of metastatic cancers
['FUNDING_R01'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-10932842
This study is looking at a new way to find and treat metastatic cancers by using a special imaging technique that targets a protein found on cancer cells, and if you qualify, you might also receive a new radiation therapy to help fight the cancer more effectively.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-10932842 on ClinicalTrials.gov |
What this research studies
This research investigates a targeted method for identifying and treating metastatic cancers by focusing on the αvβ6 integrin, a protein that is often found in high levels on cancer cells but not in normal tissues. Patients will receive a specialized imaging technique using a peptide that binds to this integrin, allowing for precise detection of tumors and metastases. If eligible, patients will also receive a novel therapy that uses radiation to target and destroy cancer cells. The study aims to improve both the detection and treatment outcomes for individuals with metastatic disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with confirmed metastatic cancers that express the αvβ6 integrin.
Not a fit: Patients without metastatic cancers or those whose tumors do not express the αvβ6 integrin may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate detection and effective treatment options for patients with metastatic cancers.
How similar studies have performed: Previous studies have shown promising results using similar targeted approaches for cancer detection and treatment, indicating potential for success in this novel application.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SUTCLIFFE, JULIE L — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: SUTCLIFFE, JULIE L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.